The bioavailability of three dipyridamole products.
Following oral administration of 75 mg of three dipyridamole commercial products in a three-way crossover design with six subjects, no statistically significant differences were found for serum concentrations at all sampling times nor for bioavailability parameters. The only exception was the higher serum concentration occurring 0.5 h after administration of Antistenocardin when compared with dipyridamole (p less than 0.05).